These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 17892516

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum.
    Bennetto-Hood C, Bryson YJ, Stek A, King JR, Mirochnick M, Acosta EP.
    HIV Clin Trials; 2009; 10(1):41-7. PubMed ID: 19362995
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.
    Hirt D, Urien S, Jullien V, Firtion G, Rey E, Pons G, Blanche S, Treluyer JM.
    Antimicrob Agents Chemother; 2006 Mar; 50(3):910-6. PubMed ID: 16495250
    [Abstract] [Full Text] [Related]

  • 7. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J, Cornforth D, Hoggard PG, Cuthbertson Z, Meaden ER, Williams I, Johnson M, Daniels E, Hsyu P, Back DJ, Khoo SH.
    Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
    [Abstract] [Full Text] [Related]

  • 8. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.
    Gingelmaier A, Kurowski M, Kästner R, Eberle J, Mylonas I, Belohradsky BH, Friese K, Grubert TA.
    AIDS; 2006 Aug 22; 20(13):1737-43. PubMed ID: 16931938
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
    Hirt D, Mentré F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Tréluyer JM, COPHAR2- ANRS Study Group.
    Br J Clin Pharmacol; 2008 Apr 22; 65(4):548-57. PubMed ID: 17922881
    [Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
    Panhard X, Goujard C, Legrand M, Taburet AM, Diquet B, Mentré F, COPHAR 1-ANRS study group.
    Br J Clin Pharmacol; 2005 Oct 22; 60(4):390-403. PubMed ID: 16187971
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.
    Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA.
    AIDS; 2001 May 25; 15(8):991-8. PubMed ID: 11399981
    [Abstract] [Full Text] [Related]

  • 19. Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
    Payen S, Faye A, Compagnucci A, Giaquinto C, Gibbs D, Gomeni R, Bressolle F, Jacqz-Aigrain E.
    Antimicrob Agents Chemother; 2005 Feb 25; 49(2):525-35. PubMed ID: 15673728
    [Abstract] [Full Text] [Related]

  • 20. Anti-HIV agents. Nelfinavir levels during pregnancy.
    TreatmentUpdate; 2004 Feb 25; 16(3):5-6. PubMed ID: 17216835
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.